BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 137
This report provides an overview of biomarkers associated with Alzheimer's disease (AD) that have potential in differential diagnosis, in following treatment, in clinical trials and drug discovery
BioPharm Reports (VennBio Ltd.), Feb 2011
This report provides an overview of biomarkers associated with Alzheimer's disease (AD) found in cerebrospinal fluid and blood, that have potential in differential diagnosis, in following treatment
BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 61
This report provides an overview of image-based biomarkers associated with Alzheimer's disease (AD), that have potential in differential diagnosis, in following treatment, in clinical trials
Datamonitor, Dec 2011, Pages: 50
Diagnostic and prognostic biomarkers will help to identify patients with early Alzheimer’s disease, while pharmacogenetic biomarkers can inform prescribing decisions and form the basis
Jain PharmaBiotech, Feb 2012, Pages: 864
disease
Pompe’s disease
Mitochondrial disorders affecting the nervous system
Spinal muscular atrophy
Biomarkers of neurodegenerative disorders
Biomarkers of Alzheimer’s disease
The ideal biomarker
John Wiley and Sons Ltd, Jan 2010, Pages: 276
Hurko
2. Biomarkers, Dementia, and Public Health: C.F. Wright , A. Hall A, F.E. Matthews, and C. Brayne
3. Imaging Biomarkers in Alzheimer’s Disease: Natalie . Ryan and Nick C. Fox
4. CSF Biomarkers
Business Insights, April 2008, Pages: 265
Mycobacteria
MRSA
Sepsis screening
Biomarkers in CNS disorders
Alzheimer's disease
Other neurodegenerative disorders
Multiple sclerosis
Traumatic brain injury
Biomarkers of CNS drug efficacy
Biomarkers
Decision Resources, Inc., Oct 2009, Pages: 32
on the indication.
- In what ways are biomarkers being explored in Parkinson’s disease compared with Alzheimer’s disease?
- How has the use of biomarkers aligned with an outcome measure for a study in ALS
Business Insights, July 2010, Pages: 198
for Alzheimer’s disease diagnosis and treatment monitoring
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Commercial PET ligands in development for AD diagnosis
Imaging biomarkers for Parkinson
Global Industry Analysts, Inc., Aug 2011, Pages: 1305
in Select CNS Diseases 57
AlzheimersDisease 57
Parkinsons DiseaseBiomarkers - Crucial for
Neuroprotectants' Effectiveness 58
Schizophrenia: An Unexploited Segment 58
OTHER THERAPEUTIC AREAS 58
Industry Experts, Sep 2010, Pages: 230
A more focused discovery process using proteins as biomarkers for various diseases has been in the development stage for quite some time now. The recent years have witnessed a more targeted approach
Jain PharmaBiotech, Feb 2012, Pages: 534
protein-1 inhibitors
Targeting GABAergic system
Pharmacogenomics of Alzheimerdisease
Personalized therapy of AD
Genotyping and AD therapeutics
Biomarkers and companion diagnostics for AD
Regulatory
John Wiley and Sons Ltd, Oct 2010, Pages: 648
Chaudhuri, Rania Harfouche, and Shiladitya Sengupta)
SECTION II: BIOMARKERS OF INJURY
6 (Biomarkers of Alzheimer’s and Parkinson’s Disease (Walter Maetzler, and Daniela Berg)
7 (Biomarkers of Cardiac Injury
BioPharm Reports (VennBio Ltd.), Jan 2011, Pages: 105
(after Alzheimer’s disease), and affects movement control. This condition develops due to the loss of dopamine-producing nerve cells in the Substantia Nigra, located in the mid brain. According to the US
Frost & Sullivan, Sep 2009, Pages: 107
with biomarker development workflow to facilitate cost-effective and accessible biomarker testing.”
Cancer biomarkers and cardiovascular biomarkers have been found to have the greatest growth among the disease
Markets and Markets, Sep 2009, Pages: 256
are starting to be offset against the savings in other areas
6.10.2.1. Alzheimer’s disease
6.10.2.1.1. Image based biomarkers
6.10.2.1.2. Genetic Markers
6.10.2.1.3. Biomarkers in blood:
6.10.2.1.4. Biomarkers
Business Insights, May 2006, Pages: 206
endpoints
Oncology
Multiple sclerosis
Rheumatoid arthritis
Alzheimer’s disease
Go/no-go decision making
Case study – VirtualScopics
Regulatory aspects of imaging technologies
Development of molecular
Markets and Markets, Feb 2012, Pages: 542
Collaborations Lead To Increasing Applications In The Market
3.3.3.1.3 Technological Advances Contribute To Growth
3.3.3.1.4 The Rising Prevalence Of The Disease Forms
3.3.3.1.5 Fda Support For Biomarker
